Feng Chi BiotechROCO:6744 +2.70%82 Net Margin % is 6.93% as of Dec. 2025, which is 39% below its 10-year median of 11.37. GuruFocus rates ROCO:6744 with a GF Score™ of 82/100 and a GF Value™ of NT$20.86 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 945 Biotechnology companies, Feng Chi Biotech ranks better than 79.47% on this metric.
The historical rank and industry rank for Feng Chi Biotech's Net Margin % or its related term are showing as below:
ROCO:6744'
s Net Margin % Range Over the Past 10 Years
Min: 8.16 Med: 11.37 Max: 14.19
Current: 8.16
ROCO:6744's Net Margin % is ranked better than 79.47% of 945
companies
in the Biotechnology industry
Industry Median: -89.33
vs ROCO:6744: 8.16
Feng Chi Biotech (ROCO:6744) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Feng Chi Biotech Net Margin % Related Terms
Feng Chi Biotech Net Margin % Historical Data
* Premium members only.
The historical data trend for Feng Chi Biotech's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6744 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Feng Chi Biotech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Feng Chi Biotech Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Feng Chi Biotech's Net Margin % distribution charts can be found below:
* The bar in red indicates where Feng Chi Biotech's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Feng Chi Biotech (ROCO:6744) has a Net Margin % of 6.93% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Feng Chi Biotech and its competitors. This is 39% below median its historical median of 11.37. Over the past decade, Feng Chi Biotech's Net Margin % has ranged from 8.16 to 14.19. According to the industry distribution chart, Feng Chi Biotech ranks #194 out of 945 companies in the Biotechnology industry, placing it in the top 20.5%.
Is Feng Chi Biotech's Net Margin % too high?
Feng Chi Biotech's current Net Margin % of 6.93% is 39% below median its 10-year median of 11.37. Over the past 10 years, this metric has ranged from a low of 8.16 to a high of 14.19. Based on the distribution chart, Feng Chi Biotech ranks #194 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Feng Chi Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Feng Chi Biotech's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Feng Chi Biotech ranks #194 out of 945 companies for Net Margin %. This places Feng Chi Biotech in the top 21% of its industry — outperforming the majority of peers. Historically, Feng Chi Biotech's own Net Margin % has ranged from 8.16 to 14.19 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Feng Chi Biotech and its competitors. Feng Chi Biotech's current Net Margin % is 6.93%, which is 39% below median its own 10-year median of 11.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Feng Chi Biotech stock overvalued right now?
Based on GuruFocus' analysis, Feng Chi Biotech (ROCO:6744) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$20.86, compared to a current price of NT$15.20 — trading 27.1% below its estimated fair value. The current Net Margin % is 6.93%, which is 39% below median its 10-year median of 11.37. Feng Chi Biotech's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Feng Chi Biotech (ROCO:6744), the current Net Margin % is 6.93% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Feng Chi Biotech (ROCO:6744) Overvalued in 2026?
Based on GuruFocus' analysis, Feng Chi Biotech stock appears to be undervalued.
The current stock price of NT$15.20 is trading 27.1% below its estimated GF Value™ of NT$20.86.
GuruFocus considers Feng Chi Biotech to be Modestly Undervalued.
Key valuation signals for ROCO:6744:
Net Margin %: 6.93% (39% below median its 10-year median of 11.37)
GF Value™: NT$20.86 vs. price of NT$15.20 (27.1% below fair value)
No single metric tells the full story. See the ROCO:6744 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Feng Chi Biotech Corp provide promotion and support for clinical testing and molecular genetic medicine research related technologies. The company's products and services include clinical testing, food testing, newborn screening, prenatal screening, iron stomach, interscience, and colony counting.
82GF Score
Get the complete analysis for ROCO:6744
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6744 has been successfully added to your 
